Brainstorm Cell Ther (BCLI) 4.14 $BCLI
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 57.23 (+0.28), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), LRE: 8.69 (+0.11), LRCX: 76.70 (-0.38), MYL: 76.06 (+2.37), NVGN: 6.54 (-0.01), BIOC: 2.88 (-0.22), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04), BCLI: 4.14 (+0.02), SANM: 20.81 (-0.03)
BrainStorm's NurOwn shows encouraging results in ALS; shares up 11% premarket
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:16AM CDT
BCLI: 4.14 (+0.02)
BrainStorm's NurOwn® Demonstrates a Statistically Significant Effect in ALS Patients
PR Newswire - Tue Apr 21, 5:55AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time today.
BCLI: 4.14 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), DOVR: 8.43 (-0.05), STCK: 18.98 (+0.32), CLVS: 92.03 (+1.78), ORMP: 7.45 (+0.08), BIND: 6.84 (-0.33), EGRX: 59.30 (-1.62), VLTC: 11.54 (+0.50), BCLI: 4.14 (+0.02), REPH: 11.88 (+1.04)
Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results
at The Street - Tue Apr 14, 9:48AM CDT
Brainstorm Cell Therapeutics (BCLI) shares are gaining as the company prepares to release a report on its phase 2a ALS treatment study.
BCLI: 4.14 (+0.02)
Brainstorm up in anticipation of NurOwn ALS results
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:52AM CDT
BCLI: 4.14 (+0.02)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:12AM CDT
NSC: 105.29 (-0.92), ARWR: 7.28 (+0.05), GWPH: 121.00 (+0.23), ALU: 3.96 (-0.07), NVGN: 6.54 (-0.01), BLDR: 12.79 (-0.09), BCLI: 4.14 (+0.02), EGY: 2.29 (-0.01), SZYM: 3.79 (-0.11)
BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
PR Newswire - Tue Apr 14, 6:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015.
BCLI: 4.14 (+0.02)
Brainstorm Rallies On Endorsement Of Competitor's Drug
Jason Napodano, CFA - at Seeking Alpha - Mon Apr 13, 10:54AM CDT
BCLI: 4.14 (+0.02)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), OSIR: 16.33 (-0.26), BCLI: 4.14 (+0.02), MDVN: 131.01 (-1.50), INO: 10.35 (-0.25), CYTX: 0.99 (+0.01), STEM: 0.61 (-0.21), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06), BLUE: 136.26 (-3.82), VRTX: 133.20 (-2.62), AMGN: 167.91 (-1.26), KERX: 11.41 (-0.32), OMER: 24.32 (-0.35), KITE: 60.58 (-0.35), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16)
Why You Should Own Brainstorm Cell Therapeutics
Jason Napodano, CFA - at Seeking Alpha - Sat Mar 28, 7:34AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics' (BCLI) CEO Tony Fiorino on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 26, 9:48AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:43AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:29AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Announces Financial Results for 2014 and Provides Business Update
PR Newswire - Thu Mar 26, 7:26AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
BCLI: 4.14 (+0.02)
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 24, 1:13PM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
ECYT: 6.17 (-0.13), SNSS: 2.69 (+0.04), BCLI: 4.14 (+0.02), XOMA: 3.60 (-0.02)
BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
PR Newswire - Thu Mar 19, 3:15PM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the financial results and answer questions.
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
PR Newswire - Wed Mar 18, 8:16AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.
BCLI: 4.14 (+0.02)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT
HOG: 57.23 (+0.28), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), LRE: 8.69 (+0.11), LRCX: 76.70 (-0.38), MYL: 76.06 (+2.37), NVGN: 6.54 (-0.01), BIOC: 2.88 (-0.22), NBG: 1.23 (+0.06), VLTC: 11.54 (+0.50), FTNT: 38.68 (-0.04), BCLI: 4.14 (+0.02), SANM: 20.81 (-0.03)
BrainStorm's NurOwn shows encouraging results in ALS; shares up 11% premarket
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:16AM CDT
BCLI: 4.14 (+0.02)
BrainStorm's NurOwn® Demonstrates a Statistically Significant Effect in ALS Patients
PR Newswire - Tue Apr 21, 5:55AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, is presenting results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) at a poster session today at the American Academy of Neurology annual meeting, taking place in Washington D.C. In addition to previously disclosed topline results, further data and analyses are being presented for the first time today.
BCLI: 4.14 (+0.02)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.46 (+0.08), FNRG: 3.11 (-0.86), BIOC: 2.88 (-0.22), NVGN: 6.54 (-0.01), AMPE: 2.73 (-0.16), TRIL: 24.21 (+2.05), CZR: 9.83 (+0.18), TLOG: 4.31 (-0.51), BCLI: 4.14 (+0.02), STDY: 9.95 (-0.19), GENE: 4.70 (-0.13), FARO: 43.44 (-1.22), ICON: 26.77 (unch), XXII: 1.35 (-0.05), XBIT: 22.94 (-4.50), UEC: 2.31 (-0.09), COOL: 1.34 (-0.06), CALA: 13.41 (-0.35), WPCS: 3.72 (-0.10), VIMC: 14.01 (+0.75)
Next Week In Biotech: Amgen, AbbVie, Biogen Earnings, UniQure CHMP, AAN Meeting
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 17, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
ABT: 48.32 (-0.14), BIIB: 401.71 (-28.57), NEO: 4.75 (-0.11), SGMO: 14.70 (-0.84), IMGN: 9.96 (-0.29), AMGN: 167.91 (-1.26), ILMN: 189.59 (-3.01), SVA: 5.10 (unch), BCLI: 4.14 (+0.02), ISRG: 505.92 (-6.85), BABY: 42.15 (-0.01), QURE: 26.09 (-0.28), NURO: 1.28 (-0.03), ABAX: 63.62 (+0.31), GWPH: 121.00 (+0.23), ALXN: 180.08 (-4.50), ABBV: 66.07 (+1.82), AMAG: 60.01 (-0.34), CAT: 84.60 (-0.19), MAA: 76.73 (-0.33), NVS: 104.28 (-1.22)
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 14, 4:58PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
HTBX: 6.89 (-0.71), DOVR: 8.43 (-0.05), STCK: 18.98 (+0.32), CLVS: 92.03 (+1.78), ORMP: 7.45 (+0.08), BIND: 6.84 (-0.33), EGRX: 59.30 (-1.62), VLTC: 11.54 (+0.50), BCLI: 4.14 (+0.02), REPH: 11.88 (+1.04)
Brainstorm Cell Therapeutics (BCLI) Stock Gains Today on Potentially Positive Phase 2a Results
at The Street - Tue Apr 14, 9:48AM CDT
Brainstorm Cell Therapeutics (BCLI) shares are gaining as the company prepares to release a report on its phase 2a ALS treatment study.
BCLI: 4.14 (+0.02)
Brainstorm up in anticipation of NurOwn ALS results
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:52AM CDT
BCLI: 4.14 (+0.02)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Apr 14, 8:12AM CDT
NSC: 105.29 (-0.92), ARWR: 7.28 (+0.05), GWPH: 121.00 (+0.23), ALU: 3.96 (-0.07), NVGN: 6.54 (-0.01), BLDR: 12.79 (-0.09), BCLI: 4.14 (+0.02), EGY: 2.29 (-0.01), SZYM: 3.79 (-0.11)
BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting
PR Newswire - Tue Apr 14, 6:00AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015.
BCLI: 4.14 (+0.02)
Brainstorm Rallies On Endorsement Of Competitor's Drug
Jason Napodano, CFA - at Seeking Alpha - Mon Apr 13, 10:54AM CDT
BCLI: 4.14 (+0.02)
Why Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
Life Sciences Report - Seeking Alpha - Thu Apr 09, 4:59PM CDT
It's the daring Phase 2-stage molecules of today that will bring patients a generation of biotech drugs that could cure certain deadly diseases tomorrow. The candidates that succeed will also energize the portfolios of investors who have exercised...
PSTI: 2.82 (-0.05), NBS: 2.91 (-0.14), OSIR: 16.33 (-0.26), BCLI: 4.14 (+0.02), MDVN: 131.01 (-1.50), INO: 10.35 (-0.25), CYTX: 0.99 (+0.01), STEM: 0.61 (-0.21), JUNO: 56.66 (-1.06), ATHX: 1.29 (-0.03), CUR: 1.94 (-0.06), BLUE: 136.26 (-3.82), VRTX: 133.20 (-2.62), AMGN: 167.91 (-1.26), KERX: 11.41 (-0.32), OMER: 24.32 (-0.35), KITE: 60.58 (-0.35), GILD: 103.69 (-1.52), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16)
Why You Should Own Brainstorm Cell Therapeutics
Jason Napodano, CFA - at Seeking Alpha - Sat Mar 28, 7:34AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics' (BCLI) CEO Tony Fiorino on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 26, 9:48AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:43AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics misses by $0.03
Seeking Alpha - at Seeking Alpha - Thu Mar 26, 7:29AM CDT
BCLI: 4.14 (+0.02)
BrainStorm Announces Financial Results for 2014 and Provides Business Update
PR Newswire - Thu Mar 26, 7:26AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
BCLI: 4.14 (+0.02)
4 Biotech Stocks Under $10 to Trade for Breakouts
at The Street - Tue Mar 24, 1:13PM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
ECYT: 6.17 (-0.13), SNSS: 2.69 (+0.04), BCLI: 4.14 (+0.02), XOMA: 3.60 (-0.02)
BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
PR Newswire - Thu Mar 19, 3:15PM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the financial results and answer questions.
BCLI: 4.14 (+0.02)
BrainStorm Cell Therapeutics to Present at 3rd Annual Regen Med Investor Day on March 25 in New York
PR Newswire - Wed Mar 18, 8:16AM CDT
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that CEO Tony Fiorino, MD, PhD, will present at the 3rd Annual Regen Med Investor Day to be held Wednesday, March 25, 2015 in New York City.
BCLI: 4.14 (+0.02)
